Interchangeability of levothyroxine sodium tablets

Interchangeability of levothyroxine sodium tablets

The article reviews scientific literature and regulatory documents on safe and efficacious use of levothyroxine medicines. Levothyroxine has less than a twofold difference between the minimal toxic concentration and minimal effective concentration. The article discusses the issue of switching betwee...

Full description

Bibliographic Details
Main Authors:	G. I. Gorodetskaya, E. A. Sokova, O. V. Muslimova, T. V. Aleksandrova, I. A. Mazerkina, S. G. Rudnev
Format:	Article
Language:	Russian
Published:	NEICON ISP LLC 2018-02-01
Series:	Ведомости Научного центра экспертизы средств медицинского применения
Subjects:	взаимозаменяемость биоэквивалентность терапевтическая эквивалентность воспроизведенные препараты препараты левотироксина натрия interchangeability bioequivalence therapeutic equivalence generic medicines levothyroxine sodium medicines
Online Access:	https://www.vedomostincesmp.ru/jour/article/view/115

Similar Items

Interchangeability of glibenclamide-containing drugs
by: G. I. Gorodetskaya, et al.
Published: (2018-02-01)

Peculiarities of approaches to assessing the interchangeability of antiepileptic drugs
by: E. O. Zhuravleva, et al.
Published: (2018-02-01)

Recommendations on the procedure for determining the interchangeability of medicinal products
by: B. K. Romanov, et al.
Published: (2018-02-01)

PROBLEM OF GENERIC REPLACEMENT: ADVANTAGES AND DISADVANTAGES
by: S. N. Tolpygina, et al.
Published: (2016-01-01)

Generic therapy: the problem of choice
by: S. N. Tolpygina
Published: (2009-06-01)

On the interchangeability of calcineurine inhibitors
by: K. E. Zatolochina, et al.
Published: (2018-02-01)

Control of adverse drug reactions in HIV/AIDS antiretroviral treatment with interchangeable medicines
by: M. V. Zhuravleva, et al.
Published: (2018-02-01)

Экономические преимущества и слабые стороны генериков в системе лекарственного обеспечения населения в России и за рубежом
Published: (2018-06-01)

TREATMENT OF OSTEOPOROSIS: CLINICAL EXPERIENCE IN USING A GENERIC DRU
by: Nataliya Vladimirovna Toroptsova, et al.
Published: (2011-03-01)

The interchangeability of drugs from line items of pharmaceutical compliance and clinical efficiency and safety
by: N. V. Verlan, et al.
Published: (2018-05-01)

Highly variable medicines - specific aspects of bioequivalence studies
by: D. P. Romodanovsky, et al.
Published: (2018-02-01)

Rome IV criteria of functional gastrointestinal diseases in evaluation of drugs interchangeability: through the eyes of a clinical pharmacologist
by: S. Yu. Serebrova, et al.
Published: (2018-02-01)

Use of clopidogrel generics in patients with acute coronary syndrome: have all issues have been resolved?
by: AN Yakovlev
Published: (2014-12-01)

The safety of biological preparations. Part 2. Safety issues of biosimilars
by: A. A. Soldatov, et al.
Published: (2018-02-01)

BIOSIMILARS, PRODUCED USING THE RECOMBINANT DNA TECHNOLOGY
by: Z. I. Avdeeva, et al.
Published: (2019-02-01)

ДЖЕНЕРИЧЕСКИЕ СТАТИНЫ В КЛИНИЧЕСКОЙ ПРАКТИКЕ: ДЕШЕВЫЕ ЗАМЕНИТЕЛИ ИЛИ ДОСТОЙНАЯ АЛЬТЕРНАТИВА БРЕНДАМ. АТОРВАСТАТИН
by: В. П. Михин, et al.
Published: (2012-04-01)

New Anticonvulsants: Interchangeability Issues and the Use of Generic Anticonvulsants in Clinical Practice
by: V. V. Arkhipov, et al.
Published: (2019-06-01)

A Comparative Parallel Study of Pharmacokinetics and Immunogenicity Following Single Intravenous Administration of Bevacizumab Biosimilar RPH-001 (Manufactured by R-Pharm Group, Russia) and Avastin® (Manufactured by F. Hoffmann-La Roche Ltd., Switzerland) in Healthy Male Volunteers
by: M. A. Kolganova, et al.
Published: (2019-09-01)

Problems of interchangeability of systemic interferons for treatment of multiple sclerosis
by: I. I. Snegireva, et al.
Published: (2018-02-01)

ASSESSMENT OF QUALITY OF GENERICS IN CARDIOLOGY: REALITY AND POSSIBILITIES
by: V. V. Yakusevich
Published: (2015-12-01)

Features and main problems of treating patients with high and very high cardiovascular risk with statins in real clinical practice (according to the data of the “PRIORITET” research)
by: S. Yu. Martsevich, et al.
Published: (2018-12-01)

Modern approaches to vaccines interchangeability
by: I. I. Snegireva, et al.
Published: (2018-02-01)

Ингаляционные антибиотики в реаниматологии (анкетный опрос врачей — анестезиологов-реаниматологов)
by: Артем Николаевич Кузовлев, et al.
Published: (2020-09-01)

Generic drugs: benefit/risk ratio
by: E. A. Ushkalova, et al.
Published: (2021-12-01)

Interchangeability of Fluconazole Drugs
by: N. D. Bunyatyan, et al.
Published: (2018-12-01)

Modern approaches to the assessment of orally inhaled products bioequivalence
by: E. S. Petrova, et al.
Published: (2018-02-01)

On the Issue of the Effectiveness of the Department for Registration of Medicines
by: A. V. Foteeva, et al.
Published: (2022-12-01)

EXPRESS METHOD FOR DETERMINATION OF ENALAPRIL AND ENALAPRILAT IN HUMAN SERUM BY HPLC-MS/MS
by: T. A. Rodina, et al.
Published: (2019-01-01)

Generic antihypertensive medications with therapeutic interchangeability requirements
by: Giulianna Gamero-Vega, et al.
Published: (2019-11-01)

Влияние сукцинатов на воспалительную реакцию: обзор литературы
by: Vladimir V. Lazarev, et al.
Published: (2023-07-01)

Reasons for allowing and refusing generic substitution and factors determining the choice of an interchangeable prescription medicine: a survey among pharmacy customers in Finland
by: Henriikka Nokelainen, et al.
Published: (2020-02-01)

PREDICTION OF THE INFLUENCE OF ORIGINAL AND GENERIC ROSUVASTATIN ON DIRECT MEDICAL COSTS OF SECONDARY PREVENTION IN PATIENTS WITH CHRONIC TYPES OF ISCHEMIC HEART DISEASE
by: E. I. Tarlovskaya, et al.
Published: (2015-08-01)

INFORMATION SYSTEM FOR EXPERT EVALUATION OF MEDICINES INTERCHANGEABILITY
by: D. P. Andreev, et al.
Published: (2018-06-01)

Planning Bioequivalence Studies in the Context of the COVID-19 Pandemic
by: D. P. Romodanovsky, et al.
Published: (2021-03-01)

Changing paradigms in bioequivalence trials submitted to the EMA for evaluation – A clinical and regulatory perspective
by: Nathaniel Refalo, et al.
Published: (2017-02-01)

EFFECT OF CRYOPRESERVED PLACENTA EXTRACT ON SOME BIOCHEMICAL INDICES OF THERAPEUTIC EFFICIENCY AND TOXICITY OF DICLOFENAC SODIUM IN ADJUVANT-INDUCED EXPERIMENTAL ARTHRITIS
by: F. V. Hladkykh, et al.
Published: (2021-09-01)

Interchangeability of Essential Phospholipid Products
by: N. D. Bunyatyan, et al.
Published: (2019-12-01)

Regulatory requirements of the European Medicines Agency for evaluation of bioequivalence of modified-release medicinal products
by: D. P. Romodanovsky, et al.
Published: (2019-03-01)

Over-the-counter naproxen in rheumatology practice: scope and therapeutic benefits
by: E. S. Filatova, et al.
Published: (2020-11-01)

Evaluation of a Proposed Approach for the Determination of the Bioequivalence Acceptance Range for Narrow Therapeutic Index Drugs in the European Union
by: Paulo Paixão, et al.
Published: (2022-10-01)